[1] |
JONES M R,KAMARA D,KARLAN B Y,et al.Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction[J]. Gynecol Oncol,2017,147(3):705-713.
|
[2] |
KHAIRALLAH A S,GENESTIE C,AUGUSTE A,et al.Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: prognostic and therapeutic implications[J]. Int J Cancer,2018,143(1):8-15.
|
[3] |
KAPELKO-SLOWIK K,SLOWIK M,SZALISKI M,et al.Elevated serum concentrations of metalloproteinases(MMP-2,MMP-9) and their inhibitors(TIMP-1,TIMP-2) in patients with Graves' orbitopathy[J]. Adv Clin Exp Med,2018,27(1):99-103.
|
[4] |
KE X,ZHANG S,XU J,et al.Non-small-cell lung cancer-induced immunosuppression by increased human regulatory T cells via Foxp3 promoter demethylation[J]. Cancer Immunol Immunother,2016,65(5):587-599.
|
[5] |
王雪梅,王丽萍. FOXP3+CD4+CD25+Tregs细胞介导机体的肿瘤免疫逃逸研究进展[J]. 实用检验医师杂志,2014,6(1):54-56.
|
[6] |
KE X,ZHANG S,WU M,et al.Tumor-associated macrophages promote invasion via Toll-like receptors signaling in patients with ovarian cancer[J]. Int Immunopharmacol,2016,40:184-195.
|
[7] |
CAO C,XU N,ZHENG X,et al.Elevated expression of MMP-2 and TIMP-2 cooperatively correlates with risk of lung cancer[J]. Oncotarget,2017,8(46):80560-80567.
|
[8] |
ERFANI N,HAMEDI-SHAHRAKI M,REZAEIFARD S,et al.FoxP3+ regulatory T cells in peripheral blood of patients with epithelial ovarian cancer[J]. Iran J Immunol,2014,11(2):105-112.
|
[9] |
KNUTSON K L,MAURER M J,PRESTON C C,et al.Regulatory T cells,inherited variation,and clinical outcome in epithelial ovarian cancer[J]. Cancer Immunol Immunother,2015,64(12):1495-1504.
|